In Research Area A, we will identify key factors that mediate the transition from health to autoimmunity and ultimately to the clinical manifestation of autoimmune disease. This will be the basis for the development of sensitive and specific biomarkers. For subsequent clinical translation, especially in diagnostics, we have a long- standing cooperation with industry partners.

In Research Area B, based on the previously identified key drivers of transition, we will use both pharmacological and non-pharmacological approaches to prevent the progression towards clinical manifestations of autoimmune disease.